nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—SLCO1A2—Spironolactone—dilated cardiomyopathy	0.334	0.429	CbGbCtD
Naloxone—CYP2C8—Spironolactone—dilated cardiomyopathy	0.133	0.171	CbGbCtD
Naloxone—ALB—Furosemide—dilated cardiomyopathy	0.118	0.152	CbGbCtD
Naloxone—ABCB1—Lisinopril—dilated cardiomyopathy	0.102	0.132	CbGbCtD
Naloxone—ABCB1—Spironolactone—dilated cardiomyopathy	0.0902	0.116	CbGbCtD
Naloxone—Cardiac fibrillation—Lisinopril—dilated cardiomyopathy	0.00469	0.125	CcSEcCtD
Naloxone—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.0016	0.0427	CcSEcCtD
Naloxone—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.00151	0.0403	CcSEcCtD
Naloxone—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00122	0.0327	CcSEcCtD
Naloxone—Irritability—Furosemide—dilated cardiomyopathy	0.00113	0.0302	CcSEcCtD
Naloxone—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00109	0.0291	CcSEcCtD
Naloxone—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000924	0.0247	CcSEcCtD
Naloxone—Sweating—Furosemide—dilated cardiomyopathy	0.000875	0.0234	CcSEcCtD
Naloxone—Irritability—Lisinopril—dilated cardiomyopathy	0.000848	0.0226	CcSEcCtD
Naloxone—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000846	0.0226	CcSEcCtD
Naloxone—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000845	0.0226	CcSEcCtD
Naloxone—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000794	0.0212	CcSEcCtD
Naloxone—Angiopathy—Furosemide—dilated cardiomyopathy	0.000743	0.0198	CcSEcCtD
Naloxone—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000732	0.0195	CcSEcCtD
Naloxone—Depression—Lisinopril—dilated cardiomyopathy	0.000683	0.0182	CcSEcCtD
Naloxone—Vomiting—Spironolactone—dilated cardiomyopathy	0.00068	0.0182	CcSEcCtD
Naloxone—Sweating—Lisinopril—dilated cardiomyopathy	0.000656	0.0175	CcSEcCtD
Naloxone—Agitation—Furosemide—dilated cardiomyopathy	0.000655	0.0175	CcSEcCtD
Naloxone—Nausea—Spironolactone—dilated cardiomyopathy	0.000635	0.017	CcSEcCtD
Naloxone—Hallucination—Lisinopril—dilated cardiomyopathy	0.000612	0.0163	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000603	0.0161	CcSEcCtD
Naloxone—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000571	0.0152	CcSEcCtD
Naloxone—Flushing—Lisinopril—dilated cardiomyopathy	0.00057	0.0152	CcSEcCtD
Naloxone—Skin disorder—Furosemide—dilated cardiomyopathy	0.000565	0.0151	CcSEcCtD
Naloxone—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000563	0.015	CcSEcCtD
Naloxone—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000558	0.0149	CcSEcCtD
Naloxone—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000554	0.0148	CcSEcCtD
Naloxone—Chills—Lisinopril—dilated cardiomyopathy	0.000551	0.0147	CcSEcCtD
Naloxone—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000538	0.0144	CcSEcCtD
Naloxone—Tension—Lisinopril—dilated cardiomyopathy	0.000525	0.014	CcSEcCtD
Naloxone—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000523	0.014	CcSEcCtD
Naloxone—Nervousness—Lisinopril—dilated cardiomyopathy	0.00052	0.0139	CcSEcCtD
Naloxone—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000502	0.0134	CcSEcCtD
Naloxone—Tremor—Lisinopril—dilated cardiomyopathy	0.000501	0.0134	CcSEcCtD
Naloxone—Pain—Furosemide—dilated cardiomyopathy	0.000498	0.0133	CcSEcCtD
Naloxone—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00046	0.0123	CcSEcCtD
Naloxone—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00046	0.0123	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000452	0.0121	CcSEcCtD
Naloxone—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000426	0.0114	CcSEcCtD
Naloxone—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000424	0.0113	CcSEcCtD
Naloxone—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000422	0.0113	CcSEcCtD
Naloxone—Asthenia—Furosemide—dilated cardiomyopathy	0.000418	0.0111	CcSEcCtD
Naloxone—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000398	0.0106	CcSEcCtD
Naloxone—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000392	0.0105	CcSEcCtD
Naloxone—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000389	0.0104	CcSEcCtD
Naloxone—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000377	0.0101	CcSEcCtD
Naloxone—Pain—Lisinopril—dilated cardiomyopathy	0.000373	0.00997	CcSEcCtD
Naloxone—Vomiting—Furosemide—dilated cardiomyopathy	0.00037	0.00988	CcSEcCtD
Naloxone—Nausea—Furosemide—dilated cardiomyopathy	0.000346	0.00923	CcSEcCtD
Naloxone—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000345	0.00922	CcSEcCtD
Naloxone—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000345	0.00922	CcSEcCtD
Naloxone—Asthenia—Lisinopril—dilated cardiomyopathy	0.000313	0.00836	CcSEcCtD
Naloxone—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000299	0.00798	CcSEcCtD
Naloxone—Vomiting—Lisinopril—dilated cardiomyopathy	0.000278	0.00741	CcSEcCtD
Naloxone—Nausea—Lisinopril—dilated cardiomyopathy	0.000259	0.00692	CcSEcCtD
Naloxone—CREB1—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000123	0.000665	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000122	0.000662	CbGpPWpGaD
Naloxone—CREB1—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000122	0.000662	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000122	0.000659	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000121	0.000657	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000121	0.000656	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000121	0.000655	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000121	0.000655	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—NR3C2—dilated cardiomyopathy	0.000121	0.000654	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00012	0.000651	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00012	0.000651	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.00012	0.00065	CbGpPWpGaD
Naloxone—CREB1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.00012	0.000646	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—CD36—dilated cardiomyopathy	0.000117	0.000633	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000116	0.00063	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	0.000116	0.000629	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—RAF1—dilated cardiomyopathy	0.000116	0.000625	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000115	0.000624	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000115	0.000623	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000114	0.000617	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000114	0.000617	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000114	0.000617	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000113	0.000613	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000113	0.000611	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000113	0.000609	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000112	0.000607	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000112	0.000606	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000112	0.000605	CbGpPWpGaD
Naloxone—CREB1—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000112	0.000603	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—RAC1—dilated cardiomyopathy	0.00011	0.000597	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00011	0.000593	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00011	0.000593	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000109	0.000591	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000109	0.000591	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000109	0.00059	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000108	0.000586	CbGpPWpGaD
Naloxone—TLR4—Immune System—RAF1—dilated cardiomyopathy	0.000108	0.000583	CbGpPWpGaD
Naloxone—CREB1—Disease—NPPA—dilated cardiomyopathy	0.000108	0.000582	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000107	0.00058	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000106	0.000574	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000106	0.000574	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VCL—dilated cardiomyopathy	0.000106	0.000574	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000106	0.000571	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000106	0.000571	CbGpPWpGaD
Naloxone—CREB1—B Cell Activation—EGFR—dilated cardiomyopathy	0.000106	0.000571	CbGpPWpGaD
Naloxone—CREB1—Disease—PSEN2—dilated cardiomyopathy	0.000104	0.000564	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CD36—dilated cardiomyopathy	0.000103	0.000559	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—RAF1—dilated cardiomyopathy	0.000103	0.000555	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000103	0.000554	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000102	0.000553	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000102	0.000552	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000102	0.00055	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000101	0.000547	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000101	0.000546	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD36—dilated cardiomyopathy	9.93e-05	0.000537	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	9.88e-05	0.000534	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	9.87e-05	0.000534	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	9.85e-05	0.000532	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	9.82e-05	0.000531	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	9.76e-05	0.000528	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—RAC1—dilated cardiomyopathy	9.75e-05	0.000527	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	9.59e-05	0.000519	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	9.59e-05	0.000519	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	9.51e-05	0.000514	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	9.46e-05	0.000512	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—RAC1—dilated cardiomyopathy	9.36e-05	0.000506	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.26e-05	0.000501	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.93e-05	0.000483	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.93e-05	0.000483	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	8.92e-05	0.000482	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	8.82e-05	0.000477	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	8.79e-05	0.000475	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	8.7e-05	0.00047	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	8.65e-05	0.000468	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.64e-05	0.000467	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	8.55e-05	0.000462	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	8.49e-05	0.000459	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	8.47e-05	0.000458	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—EGFR—dilated cardiomyopathy	8.44e-05	0.000456	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.44e-05	0.000456	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.41e-05	0.000455	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	8.34e-05	0.000451	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	8.31e-05	0.000449	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	8.3e-05	0.000449	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	8.24e-05	0.000445	CbGpPWpGaD
Naloxone—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	8.19e-05	0.000443	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	8.18e-05	0.000442	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	8.12e-05	0.000439	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	8.11e-05	0.000438	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	8.11e-05	0.000438	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	8.04e-05	0.000435	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8e-05	0.000433	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.98e-05	0.000431	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—EGFR—dilated cardiomyopathy	7.77e-05	0.00042	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	7.75e-05	0.000419	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.7e-05	0.000417	CbGpPWpGaD
Naloxone—ALB—Metabolism—TAZ—dilated cardiomyopathy	7.7e-05	0.000416	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	7.62e-05	0.000412	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—NPPA—dilated cardiomyopathy	7.59e-05	0.000411	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	7.54e-05	0.000407	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	7.52e-05	0.000406	CbGpPWpGaD
Naloxone—TLR4—Immune System—EGFR—dilated cardiomyopathy	7.4e-05	0.0004	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.38e-05	0.000399	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—RAF1—dilated cardiomyopathy	7.32e-05	0.000396	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.3e-05	0.000395	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	7.3e-05	0.000395	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.28e-05	0.000393	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	7.18e-05	0.000388	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	7.18e-05	0.000388	CbGpPWpGaD
Naloxone—CREB1—Immune System—ITGB1—dilated cardiomyopathy	7.06e-05	0.000382	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—EGFR—dilated cardiomyopathy	7.03e-05	0.00038	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	7.03e-05	0.00038	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	7.01e-05	0.000379	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7e-05	0.000378	CbGpPWpGaD
Naloxone—ALB—Metabolism—SDHA—dilated cardiomyopathy	6.97e-05	0.000377	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.86e-05	0.000371	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.82e-05	0.000369	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	6.75e-05	0.000365	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	6.7e-05	0.000362	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.52e-05	0.000352	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.51e-05	0.000352	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.48e-05	0.00035	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.48e-05	0.00035	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—RAF1—dilated cardiomyopathy	6.46e-05	0.00035	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.46e-05	0.000349	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.46e-05	0.000349	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.38e-05	0.000345	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	6.23e-05	0.000337	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.21e-05	0.000336	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—RAF1—dilated cardiomyopathy	6.21e-05	0.000336	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.19e-05	0.000335	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	6.1e-05	0.00033	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.03e-05	0.000326	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD36—dilated cardiomyopathy	6.03e-05	0.000326	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.01e-05	0.000325	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	5.98e-05	0.000323	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AGT—dilated cardiomyopathy	5.94e-05	0.000321	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AGT—dilated cardiomyopathy	5.92e-05	0.00032	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.91e-05	0.00032	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.84e-05	0.000316	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.82e-05	0.000315	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.72e-05	0.000309	CbGpPWpGaD
Naloxone—CREB1—Immune System—RAC1—dilated cardiomyopathy	5.68e-05	0.000307	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.67e-05	0.000306	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.67e-05	0.000306	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	5.51e-05	0.000298	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.43e-05	0.000294	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	5.42e-05	0.000293	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.39e-05	0.000292	CbGpPWpGaD
Naloxone—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	5.33e-05	0.000288	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.27e-05	0.000285	CbGpPWpGaD
Naloxone—CREB1—Disease—RAC1—dilated cardiomyopathy	5.24e-05	0.000283	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AGT—dilated cardiomyopathy	5.19e-05	0.000281	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.1e-05	0.000276	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	5.06e-05	0.000273	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.03e-05	0.000272	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—EGFR—dilated cardiomyopathy	5.02e-05	0.000271	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.98e-05	0.00027	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.97e-05	0.000269	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.83e-05	0.000261	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.79e-05	0.000259	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.79e-05	0.000259	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.78e-05	0.000259	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TNF—dilated cardiomyopathy	4.78e-05	0.000258	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.73e-05	0.000256	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.71e-05	0.000255	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.59e-05	0.000248	CbGpPWpGaD
Naloxone—ALB—Hemostasis—CD36—dilated cardiomyopathy	4.54e-05	0.000246	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.45e-05	0.000241	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—EGFR—dilated cardiomyopathy	4.43e-05	0.00024	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	4.42e-05	0.000239	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.39e-05	0.000237	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.36e-05	0.000236	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.31e-05	0.000233	CbGpPWpGaD
Naloxone—ALB—Hemostasis—RAC1—dilated cardiomyopathy	4.28e-05	0.000232	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.27e-05	0.000231	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.26e-05	0.00023	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.25e-05	0.00023	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.25e-05	0.00023	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.25e-05	0.00023	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.16e-05	0.000225	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	4.16e-05	0.000225	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.14e-05	0.000224	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.13e-05	0.000223	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.12e-05	0.000223	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.11e-05	0.000222	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.06e-05	0.00022	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.05e-05	0.000219	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.95e-05	0.000213	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GPX1—dilated cardiomyopathy	3.87e-05	0.000209	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.82e-05	0.000207	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CD36—dilated cardiomyopathy	3.77e-05	0.000204	CbGpPWpGaD
Naloxone—CREB1—Immune System—RAF1—dilated cardiomyopathy	3.76e-05	0.000204	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	3.76e-05	0.000203	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.75e-05	0.000203	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.73e-05	0.000201	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	3.72e-05	0.000201	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.68e-05	0.000199	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.67e-05	0.000198	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.66e-05	0.000198	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.6e-05	0.000195	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.55e-05	0.000192	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	3.54e-05	0.000192	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AGT—dilated cardiomyopathy	3.51e-05	0.00019	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AGT—dilated cardiomyopathy	3.5e-05	0.000189	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.49e-05	0.000189	CbGpPWpGaD
Naloxone—CREB1—Disease—RAF1—dilated cardiomyopathy	3.48e-05	0.000188	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AGT—dilated cardiomyopathy	3.4e-05	0.000184	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.26e-05	0.000177	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.21e-05	0.000173	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.1e-05	0.000167	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AGT—dilated cardiomyopathy	3.07e-05	0.000166	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.04e-05	0.000165	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3e-05	0.000162	CbGpPWpGaD
Naloxone—ALB—Hemostasis—RAF1—dilated cardiomyopathy	2.84e-05	0.000154	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.83e-05	0.000153	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.82e-05	0.000152	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.71e-05	0.000147	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.66e-05	0.000144	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AGT—dilated cardiomyopathy	2.59e-05	0.00014	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—dilated cardiomyopathy	2.58e-05	0.00014	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.47e-05	0.000134	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.46e-05	0.000133	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.43e-05	0.000132	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.43e-05	0.000131	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.4e-05	0.00013	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—dilated cardiomyopathy	2.38e-05	0.000129	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AGT—dilated cardiomyopathy	2.3e-05	0.000124	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.15e-05	0.000116	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.13e-05	0.000115	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.09e-05	0.000113	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	1.9e-05	0.000103	CbGpPWpGaD
Naloxone—ALB—Metabolism—GPX1—dilated cardiomyopathy	1.89e-05	0.000102	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	1.85e-05	0.0001	CbGpPWpGaD
Naloxone—ALB—Metabolism—CD36—dilated cardiomyopathy	1.84e-05	9.96e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.8e-05	9.72e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.67e-05	9.03e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	1.67e-05	9.02e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.66e-05	9e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—AGT—dilated cardiomyopathy	1.66e-05	8.97e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	1.66e-05	8.96e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.61e-05	8.73e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.59e-05	8.62e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.46e-05	7.89e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.45e-05	7.86e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.23e-05	6.67e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.09e-05	5.91e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.02e-05	5.52e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	9.95e-06	5.38e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	8.96e-06	4.84e-05	CbGpPWpGaD
